A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Nilotinib (Primary) ; Cetuximab
- Indications Colorectal cancer; Head and neck cancer
- Focus Adverse reactions
- 01 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 01 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 11 Feb 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.